← Back to Clinical Trials
Recruiting NCT06415266

NCT06415266 Assessment the sExual Quality of Life in Breast Cancer Patients Receiving oncoSexology Supportive Care on Proactive Versus On-request

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06415266
Status Recruiting
Phase
Sponsor Institut du Cancer de Montpellier - Val d'Aurelle
Condition Breast Cancer
Study Type INTERVENTIONAL
Enrollment 264 participants
Start Date 2024-08-09
Primary Completion 2027-08

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Quality of life questionnaire (QLQ)Satisfaction surveyAssessment of patient needs in the field of oncosexology

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 264 participants in total. It began in 2024-08-09 with a primary completion date of 2027-08.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The study compares the quality of sexual life of breast cancer patients under two types of oncoSexology supportive care : personalized supportive care versus on-request. The aim is to improve the quality of sexual life of these patients.

Eligibility Criteria

Inclusion Criteria: * Woman or man at least 18 years old * Diagnosis of infiltrating breast cancer regardless of the biological characteristics of the tumor * Standard treatment by surgery, radiotherapy and/or chemotherapy, completed a maximum of 3 months ago with the exception of post-neoadjuvant treatments (chemotherapy, poly(ADP-ribose) polymerase (PARP) inhibitor, immunotherapy, targeted treatment, ...) which must have been started less than 3 months previously * Patient with sufficient command of the French language to be able to answer the questionnaires * Patient having given informed, written and express consent. * Affiliation to the French Social Security System * Willingness and ability to comply with scheduled visits, treatment plan and other study procedures Exclusion Criteria: * Patient already taken cared of in oncosexology. The following are not criteria for non-inclusion (a previous single consultation without treatment, use of local vaginal treatments) * Metastatic disease * Patient under guardianship, curatorship or safeguard of justice

Contact & Investigator

Central Contact

Aurore MOUSSION

✉ DRCI-icm105@icm.unicancer.fr

📞 04 67 61 31 02

Principal Investigator

Véronique D'HONDT, Dr

PRINCIPAL INVESTIGATOR

Institut du Cancer de Montpellier (ICM)

Frequently Asked Questions

Who can join the NCT06415266 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06415266 currently recruiting?

Yes, NCT06415266 is actively recruiting participants. Contact the research team at DRCI-icm105@icm.unicancer.fr for enrollment information.

Where is the NCT06415266 trial being conducted?

This trial is being conducted at Saint-Herblain, France, Vandœuvre-lès-Nancy, France, Lyon, France, Montpellier, France and 5 additional locations.

Who is sponsoring the NCT06415266 clinical trial?

NCT06415266 is sponsored by Institut du Cancer de Montpellier - Val d'Aurelle. The principal investigator is Véronique D'HONDT, Dr at Institut du Cancer de Montpellier (ICM). The trial plans to enroll 264 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology